Performance Measurement and Quality Improvement Initiatives for Bladder Cancer Care

Benjamin T. Ristau, Marc C. Smaldone

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Purpose of Review: Bladder cancer care is costly due to long surveillance periods for non-muscle-invasive bladder cancer (NMIBC) and comorbidities associated with the surgical treatment of muscle-invasive bladder cancer (MIBC). We reviewed current evidence-based practices and propose quality metrics for NMIBC and MIBC. Recent Findings: For patients with NMIBC, we propose four categories of candidate quality metrics: (1) appropriate use of imaging, (2) re-staging transurethral resection of bladder tumor, (3) perioperative intravesical chemotherapy, and (4) induction and maintenance BCG in high-risk NMIBC. For patients with MIBC, we propose eight candidate quality measures: (1) neoadjuvant chemotherapy, (2) multidisciplinary consultation, (3) urinary diversion teaching, (4) appropriate perioperative antibiotics, (5) venous thromboembolic prophylaxis, (6) lymphadenectomy, (7) monitoring of complications, and (8) inclusion of enhanced recovery after surgery protocols. Summary: Marked variation in evidence-based practice exists among patients with bladder cancer and represents opportunity for quality improvement. Regional and national physician-led collaboratives may be the best vehicle to achieve quality improvement in bladder cancer.

Original languageEnglish
Article number100
JournalCurrent Urology Reports
Volume19
Issue number12
DOIs
StatePublished - Dec 1 2018

Keywords

  • Bladder cancer
  • Evidence-based
  • Outcome measurement
  • Performance measurement
  • Quality improvement

Fingerprint

Dive into the research topics of 'Performance Measurement and Quality Improvement Initiatives for Bladder Cancer Care'. Together they form a unique fingerprint.

Cite this